Navigation Links
The First Direct Structural Evidence of SV2A has Been Revealed Thanks to Protein Tomography(TM), and Published in BBRC
Date:9/9/2008

Summary: Protein Tomography(TM) has yet Again Provided Structural Proof of a Drug Target Function. A Study Performed by Sidec and UCB, Characterizes the Target of Anti-Epileptic Drug in Situ Where Two Major Conformations

Have Been Identified

STOCKHOLM, September 9 /PRNewswire/ -- Sidec AB has together with UCB published the first direct structural evidence of the molecular mechanism of the Synaptic Vesicle protein 2A (SV2A) in mouse brain tissue. SV2A is the unique brain-binding site of the second generation anti-epileptic drug levetiracetam (LEV; Keppra(R) is a trademark of UCB). The result shows the first direct structural proof of the "alternating access model" that has been proposed for the MFS class of transporter proteins. The "alternating access model" postulates that the trans-membrane MFS class proteins can exist in two different conformations; as a valve that can be open to either side of the membrane. Prior to this Protein Tomography(TM) study, great efforts were made to prove this mechanism both by x-ray crystallography and indirectly by site directed mutagenesis.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/294289 )

"Obtaining structures of trans-membrane proteins is notoriously difficult, and the success of such endeavours is difficult to predict. This study demonstrates that Protein Tomography(TM) is well adopted to study structure, function and flexibility of trans-membrane proteins," says Anders Aberg, CSO at Sidec.

The publication is available on-line in the journal Biochemical and Biophysical Research Communications, August 7, 2008. http://www.elsevier.com/locate/ybbrc

About Sidec:

Sidec offers Protein Tomography((TM)) as collaborative contract research projects. The multidisciplinary team of experts at Sidec can provide a strong IP strategy and proven product differentiation to the bio-pharmaceutical industry. Sidec offers their partners a unique visual guidance for target- lead and CD selection to secure a competitive advantage in the drug design strategy. More information can be found on our homepage where we continuously update academic collaborations and industrial partnerships as well as recent publications.

For more information, please contact:

Mr. Hans Johansson, CEO

Phone: +46(8)560-02-102

E-mail: hans.johansson@sidec.com

http://www.sidec.com


'/>"/>
SOURCE Sidec AB
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM ... sells medical devices and wearable sleep respiratory products in ... agreement with Hongyuan Supply Chain Management Co., Ltd. (hereinafter ... 2016, to develop Dehaier,s new Internet medical technology business. ... leverage Hongyuan Supply Chain,s sales platform to reach Dehaier,s ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
Breaking Medicine News(10 mins):